scispace - formally typeset
H

Hiroshi Nishihara

Researcher at Keio University

Publications -  677
Citations -  17201

Hiroshi Nishihara is an academic researcher from Keio University. The author has contributed to research in topics: Medicine & Terpyridine. The author has an hindex of 62, co-authored 616 publications receiving 14683 citations. Previous affiliations of Hiroshi Nishihara include Tokyo University of Science & Ochanomizu University.

Papers
More filters
Journal ArticleDOI

First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion

TL;DR: Ductal adenocarcinoma of the prostate is a rare prostate cancer variant and associated with higher stage and greater risk of mortality and optimal systemic therapy is not known.
Journal ArticleDOI

Electron-Beam Writing Fabrication of Periodic Structure for Quasi-Phase-Matching Second-Harmonic Generation in Dimethyl Nitrophenyl Pyrazole Crystal Waveguide

TL;DR: In this article, a periodic structure for quasi-phase matching (QPM) second-harmonic generation (SHG) in 3,5-dimethyl-1-(4-nitrophenyl) pyrazole (DMNP) by electron-beam (EB) writing was demonstrated.
Journal ArticleDOI

Clinical predominance of whole‐exome sequencing to evaluate microsatellite instability status

TL;DR: In this article , the concordance among the MSIsensor score obtained from whole-exome sequencing (WES), which could be a futuristic clinical cancer sequencing method, using only tumor tissues, MSI-PCR results, and immunohistochemistry (IHC) results to analyze various solid cancer types.
Journal ArticleDOI

CW Laser Oscillation in Z-Cut Nd-Diffused Ti:MgO:LiNbO3 Waveguides

TL;DR: In this article, a prototype waveguide laser of 14mm long was fabricated, and CW oscillation was achieved at a wavelength of 1085 nm by optical pumping at 809 nm.
Journal Article

[Crosstalk of Cancer Genomic Test and Cancer Immune Therapy].

TL;DR: The conventional MSI test is consist of direct PCR method to amplify the microsatellite region using DNA derived from tumor specimen as a companion diagnostic for pembrolizumab CDx, while the recent comprehensive genomic profiling test such as FoundationOne CDx also evaluate the MSI status.